Sanam Loghavi, MD

Articles by Sanam Loghavi, MD

Ruben Mesa, MDUncategorized | June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
Ruben Mesa, MDUncategorized | July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
Ruben Mesa, MDThe HemOnc Pulse Live | June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
Naveen Pemmaraju, MDThe HemOnc Pulse Live | July 26, 2024
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 23, 2024
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Ruben Mesa, MDVideo Insights | June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
Ruben Mesa, MDVideo Insights | June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | May 13, 2024
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 8, 2024
Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.
Sanam Loghavi, MDThe HemOnc Pulse Live | May 13, 2024
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients," Dr. Loghavi said.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | September 14, 2023
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.